M.D. Anderson Cancer Center
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
Primary Objectives * To determine the overall proportion of high-risk MM participants achieving sustained MRD-negative CR status after the completion of the treatment plan including in-vivo purging with elranatamab, auto-HCT, and post-transplant maintenance therapy. Sustained MRD-negativity is defined as MRD-negative status in two assessments, at least 1-year apart, without any MRD-positive status in between. * To determine the proportion of patients with clonal plasma cell negative autograft collection in participants with high-risk MM. Secondary Objectives * To assess the impact of elrana…
Inclusion Criteria: 1. Transplant eligible patients with newly diagnosed multiple myeloma (NDMM). 2. High-risk multiple myeloma\* 3. Participants with disease response ≥ PR to induction therapy 4. Age ≥ 18 and ≤ 75. Non-English-speaking participants are eligible. 5. Karnofsky performance status ≥70 (Appendix A). 6. Adequate liver function (total bilirubin ≤1.5X ULN; ALT ≤2.5 X ULN) 7. Estimated creatinine clearance ≥40 mL/min. Creatinine clearance may be calculated using Cockcroft-Gault, estimated glomerular filtration rate (Modification of Diet in Renal Disease \[MDRD\]), or Chronic Kidney D…
Given by SC
Given by PO
Given by SC
Given by IV
Given by PO
Given by IV
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.